Tilray Interest Expense 2011-2026 | TLRY

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Tilray

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
46.6 M	39.7 M	30.9 M	25.6 M	2.5 M	2.01 M	12 K	-1 K	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
46.6 M	-1 K	18.4 M

Quarterly Interest Expense Tilray

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	12.6 M	-	-	-	-4.4 M	-	1.21 M	-18.4 M	-33 M	-51.4 M	71 M	65.6 M	191 K	115 M	1.52 M	1.8 M	38 K	-333 K	-4.65 M	-	1.12 M	1.22 M	3.84 M	-	225 K	76 K	121 K	-	9 K	-20 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
115 M	-51.4 M	7.12 M

Interest Expense of other stocks in the Drug manufacturers industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Alimera Sciences ALIM	10.2 M	-	-	$ 142 M	USA
Aerie Pharmaceuticals AERI	-27.9 M	-	-	$ 754 M	USA
Canopy Growth Corporation CGC	74.6 M	$ 1.14	-1.72 %	$ 123 M	Canada
AcelRx Pharmaceuticals ACRX	1.12 M	-	7.5 %	$ 6.35 M	USA
Adamis Pharmaceuticals Corporation ADMP	4.92 K	-	0.86 %	$ 117 M	USA
Catalent CTLT	-4 M	-	-	$ 11.5 B	USA
Agile Therapeutics AGRX	1.42 M	-	10.11 %	$ 58.2 M	USA
Zynerba Pharmaceuticals ZYNE	80.2 K	-	-	$ 55.5 M	USA
DURECT Corporation DRRX	2.24 M	-	-	$ 50.1 M	USA
Eagle Pharmaceuticals EGRX	4.04 M	-	-39.89 %	$ 27.7 M	USA
Endo International plc ENDP	350 M	-	-	$ 28.9 M	Irlanda
Evoke Pharma EVOK	500 K	-	-	$ 36.6 M	USA
HEXO Corp. HEXO	20.1 M	-	2.45 %	$ 38.1 M	Canada
Emergent BioSolutions EBS	87.9 M	$ 12.36	1.64 %	$ 633 M	USA
Athenex ATNX	25.8 M	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	13 M	$ 21.55	0.05 %	$ 2.05 B	France
Evolus EOLS	127 K	$ 6.65	-0.3 %	$ 412 M	USA
Harrow Health HROW	21.3 M	$ 49.0	-2.04 %	$ 1.6 B	USA
China Pharma Holdings CPHI	27.4 K	$ 1.21	-9.02 %	$ 21.1 M	China
Organogenesis Holdings ORGO	20 K	$ 5.18	-	$ 682 M	USA
Pacira BioSciences PCRX	-373 K	$ 25.88	-0.73 %	$ 1.2 B	USA
Bausch Health Companies BHC	-28 M	$ 6.95	-0.57 %	$ 2.54 B	Canada
Lannett Company LCI	58 M	-	1.15 %	$ 7.11 M	USA
Rockwell Medical RMTI	2.3 M	$ 0.83	2.18 %	$ 19.4 M	USA
Neoleukin Therapeutics NLTX	12 K	-	-	$ 193 M	Canada
Cumberland Pharmaceuticals CPIX	606 K	$ 3.98	0.51 %	$ 56 M	USA
Sonoma Pharmaceuticals SNOA	-10 K	$ 3.64	0.64 %	$ 4.52 M	USA
Sundial Growers SNDL	81 K	$ 1.66	0.61 %	$ 3.37 M	Canada
PetIQ PETQ	38.3 M	-	1.64 %	$ 400 M	USA
Jupiter Wellness JUPW	-5.37 M	-	-	$ 33.6 M	USA
Veru VERU	862 K	$ 2.14	-1.38 %	$ 289 M	USA
Perrigo Company plc PRGO	900 K	$ 13.92	-0.14 %	$ 1.91 B	USA
ProPhase Labs PRPH	764 K	$ 0.45	-1.28 %	$ 7.13 M	USA
Radius Health RDUS	18.3 M	-	-	$ 1.42 B	USA
cbdMD YCBD	-29.5 K	$ 1.35	-0.37 %	$ 5.82 M	USA
Recro Pharma REPH	9.96 M	-	-4.76 %	$ 65.3 M	USA
Relmada Therapeutics RLMD	5.15 M	$ 4.83	6.62 %	$ 145 M	USA
OptiNose OPTN	19.5 M	-	-	$ 1.08 B	USA
Assertio Holdings ASRT	2.78 M	$ 9.07	-1.41 %	$ 644 M	USA
Solid Biosciences SLDB	652 K	$ 5.64	-1.05 %	$ 230 M	USA
SCYNEXIS SCYX	3.13 M	$ 0.63	4.43 %	$ 30.1 M	USA
Tricida TCDA	17.6 M	-	-	$ 3.25 M	USA
TherapeuticsMD TXMD	300 K	$ 1.63	-0.61 %	$ 17 M	USA
Viatris VTRS	592 M	$ 12.45	-0.72 %	$ 15.1 B	USA